MedTrace Logo

Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms

NCT06889779 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2026-03-11

No results posted yet for this study

Summary

A randomized, placebo-controlled, double-blind clinical study to evaluate the efficacy of two different mixes of HMO-2'-O-fucosyllactose (HMO-2FL) + Humiome® Post LB postbiotic (postbiotic-LB) on Gastrointestinal Symptoms in individuals with Irritable Bowel Syndrome (IBS)

Conditions

  • IBS (Irritable Bowel Syndrome)

Interventions

DIETARY_SUPPLEMENT

MIX 1

Humiome® Post LB postbiotic 300 mg , Human Milk Oligosaccharides 2'-Ofucosyllactose 300 mg 1 capsule per day Orally

DIETARY_SUPPLEMENT

MIX 2

Humiome® Post LB postbiotic 100 mg Human Milk Oligosaccharides 2'-O-fucosyllactose 500 mg 1 capsule per day Orally

DIETARY_SUPPLEMENT

Placebo

Microcrystalline cellulose 1 capsule per day Orally

Sponsors & Collaborators

  • dsm-firmenich Switzerland AG

    lead INDUSTRY

Principal Investigators

  • Mehdi Sadaghian, PhD · dsm-firmenich Switzerland AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-27
Primary Completion
2026-05-30
Completion
2026-07-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06889779 on ClinicalTrials.gov